News Genmab A/S

Equities

GMAB

DK0010272202

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:54 2024-05-14 am EDT			5-day change	1st Jan Change
2,025 ^DKK	+1.76%		+0.65%	-6.03%

May. 14	Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress	CI
May. 03	GENMAB : A good start to 2024; guidance unchanged

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress	May. 14	BU
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress	May. 14	CI
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress	May. 14	GL
Transactions in Connection with Share Buy-back Program	May. 13	GL
Genmab A/S : has published its Articles of Association	May. 08	PU
Genmab A/S : Articles of association dated May 07, 2024 – English	May. 08	PU
Capital Increase in Genmab as a Result of Employee Warrant Exercise	May. 07	GL
Transactions in Connection with Share Buy-back Program	May. 06	GL
GENMAB : A good start to 2024; guidance unchanged	May. 03
Genmab Posts Q1 Net Profit Surge; Revenue Jumps	May. 02	MT
Genmab A/S : Investor Presentation - May 2024	May. 02	PU
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance	May. 02	MT
Transcript : Genmab A/S, Q1 2024 Earnings Call, May 02, 2024	May. 02
Genmab A/S : Interim Report for the First Quarter of 2024	May. 02	PU
Genmab A/S : First Quarter 2024 Financial Results Presentation	May. 02	PU
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Genmab Announces Financial Results for the First Quarter of 2024	May. 02	GL
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer	Apr. 30	MT
Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment	Apr. 29	MT
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer	Apr. 29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 01:08 pm EDT